Alfuzosin Disease Interactions
There are 5 disease interactions with alfuzosin.
Alfuzosin (applies to alfuzosin) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C). The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.
Alfuzosin (applies to alfuzosin) QT prolongation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome
Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.
Alfuzosin (applies to alfuzosin) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Caution should be exercised when alfuzosin is administered in patients with severe renal impairment as safety data is limited on these patients (CrCl < 30 mL/min).
Alpha-1 blockers (applies to alfuzosin) hypotension
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Syncope, Dehydration
Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations. Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose. However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days. Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects. Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes. Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs. Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling. During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur. Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized. If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.
Antiadrenergic agents (applies to alfuzosin) cataracts
Moderate Potential Hazard, Moderate plausibility.
Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents. If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings). There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.
Switch to professional interaction data
Alfuzosin drug interactions
There are 497 drug interactions with alfuzosin.
Alfuzosin alcohol/food interactions
There are 2 alcohol/food interactions with alfuzosin.
More about alfuzosin
- alfuzosin consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (82)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: alpha blockers
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Flomax
Flomax (tamsulosin) is used to improve urination in men with benign prostatic hyperplasia. Includes ...
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Tepezza
Tepezza (teprotumumab) infusion is used for thyroid eye disease (TED). Includes Tepezza side ...
Proscar
Proscar (finasteride) is used to treat benign prostatic hyperplasia (enlarged prostate). Includes ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Dutasteride
Dutasteride (brand name Avodart) is used to treat benign prostatic hyperplasia (enlarged prostate ...
Terazosin
Terazosin is used to treat hypertension (high blood pressure) and benign prostatic hyperplasia ...
Doxazosin
Doxazosin is used to treat hypertension (high blood pressure) and benign prostatic hyperplasia ...
Prazosin
Prazosin systemic is used for anxiety and stress, benign prostatic hyperplasia, heart failure, high ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.